TSAAI 2023 Annual Meeting
TSAAI's 2023 Annual Meeting seeks to educate allergists on a variety of topics relevant to the treatment of allergy, asthma, and immunology. Join us and our nationally recognized speakers to learn more about Peanut AIT, EoE, Asthma and the role of biologics, Atopic Dermatitis, Mast Cell Disorders, treating children with recurrent infections, and Spirometry.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and Tennessee Society of Allergy, Asthma and Immunology. The American College of Allergy, Asthma and Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 7 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity
Allied health professionals
At the conclusion of this meeting, learners should be able to:
1. Utilize new therapies to treat atopic dermatitis.
2. Confidently select the best biologic therapy for severe asthma patients.
3. Implement oral peanut immunotherapy in their practice.
TSAAI 2023 Annual Meeting
Dollywood’s DreamMore Conference Center, Pigeon Forge, TN
August 11-13, 2023
Friday, August 11, 2023
3:30 – 5:00 pm Exhibitors setup & Check-In
6:15 – 7:00 pm Welcome reception
Saturday, August 12, 2023
7:15 – 7:45 am Attendee Check-In
7:15 – 7:45 am Breakfast & Exhibits
7:45 – 8:00 am Introduction, Karthik Krishnan, MD
8:00 – 9:00 am Peanut AIT (Who, Why, and How), Richard Wasserman, MD
Q & A
9:00 – 10:00 am Update of Eosinophilic Esophagitis and Role of Biologic Therapy, Jay Lieberman, MD
Q & A
10:00 – 10:30 am Break & exhibits
10:30 – 11:30 am An Iconoclastic Review of Spirometry: A New Approach to Interpretation, John Kelso, MD
Q & A
11:30 – 12:30 pm How Do We Define Remission in Asthma and Do Biologics Achieve That in Our Patients?, Nicole Chase, MD
Q & A
1:00 pm Non-CME Lunch & Learn provided by Takeda, “Hereditary Angioedema (HAE): Navigating Family Dynamics for Attack Prevention” , Douglas Lotz, MD
Sunday, August 13, 2023
7:15 – 8:00 am Breakfast & Exhibits
8:00 – 9:00 am Update on Current and Emerging Therapies for Atopic Dermatitis, Mark Boguniewicz, MD
Q & A
9:00 – 10:00 am Anaphylaxis, Mast Cell Disorders or Something Else, Anne Maitland, MD
Q & A
10:00 – 10:30 am Break & Exhibits
10:30 – 11:30 am Approach to the Child with Recurrent Infections: When to Worry and What to Do, Monica Lawrence, MD
Q & A
11:30 am Meeting adjourn
*please stay for a short business meeting & door prize drawing!
Disclosure Policy and Disclosures
As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewer, and other individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.
Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. (Examples of ineligible companies include: Advertising, marketing, or communication firms whose clients are ineligible companies; bio-medical startups that have begun a governmental regulatory approval process; compounding pharmacies that manufacture proprietary compounds; device manufacturers or distributors; diagnostic labs that sell proprietary products; growers, distributors, manufacturers or sellers of medical foods and dietary supplements; manufacturers of health-related wearable products; pharmaceutical companies or distributors; pharmacy benefit managers; reagent manufacturers or sellers).
The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.
Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.
Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI.
All relevant financial relationships with inelgible companies have been mitigated.
Mark Boguniewicz, MD, Speaker
Advisor: Regeneron, Sanofi Genzyme, AbbVie, LEO Pharma, Lilly, Pfizer, Amgen, Incyte, Janssen
Researcher: Regeneron, Sanofi Genzyme, Incyte
Nicole Chase, MD, Speaker
Advisor: Amgen, AstraZeneca, ARS, Genentech, Novartis, Regeneron, Sanofi, GlaxoSmithKline, Hikma
Consultant: Regeneron, Sanofi
Speaker: Amgen, AstraZeneca, ARS, Incyte, Regeneron, GlaxoSmithKline
Independent Contractor: AstraZeneca, Genentech
Monica Lawrence, MD, Speaker
Advisor: Horizon Therapeutics, Enzyvant Therapeutics
Researcher: Regeneron, GSK, CSL Behring
Jay Lieberman, MD, Speaker
Advisor: Aquestive, ALK
Consultant: ALK, Siolta, AbbVie
Researcher: DBV, Regeneron, Novartis
Anne Maitland, MD, Speaker
Speaker: Blueprint Medicines
Richard Wasserman, MD, Speaker
Consultant: Aimmune, CSL Behring, Grifols, Takeda
Researcher: Cour Pharmaceuticals, Takeda
Speaker: CSL Behring, GSK, Grifols, Takeda
Stock: Belhaven Biopharma
John Kelso, MD, Speaker: No relevant financial relationships with ineligible companies to disclose
Karthik Krishnan, MD, Program Chair and Physician Planner: No relevant financial relationships with ineligible companies to disclose
Michelle Kittle, Meeting Coordinator: No relevant financial relationships with ineligible companies to disclose
- 7.00 AMA PRA Category 1 Credit™
- 7.00 Attendance